Drug Eluting Stent News and Research

RSS

A drug-eluting stent (DES) is a coronary stent (a scaffold) placed into narrowed, diseased coronary arteries that slowly releases a drug to block cell proliferation. This prevents fibrosis that, together with clots (thrombus), could otherwise block the stented artery, a process called restenosis.

Johnson & Johnson announces financial results for the third quarter of 2009

Johnson & Johnson today announced sales of $15.1 billion for the third quarter of 2009, a decrease of 5.3% as compared to the third quarter of 2008. Operational results declined 2.8% and the negative impact of currency was 2.5%. Domestic sales declined 8.1%, while international sales declined 2.5%, reflecting operational growth of 2.4% and a negative currency impact of 4.9%.

13 Oct 2009

HCRI commences patient enrollment in dual antiplatelet therapy study

The Harvard Clinical Research Institute (HCRI) announced today that the first patients have been enrolled in the DAPT Study, marking the official initiation of the four-year clinical trial to investigate the duration of dual antiplatelet therapy (DAPT, the combination of aspirin and a thienopyridine/antiplatelet medication to reduce the risk of blood clots) following drug-eluting stent implantations.

3 Oct 2009

HORIZONS-AMI clinical trial demonstrates efficacy of drug-eluting stent

Late-breaking data from the landmark HORIZONS-AMI clinical trial, presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, demonstrated that after two years, in heart attack patients, the use of a drug-eluting stent (paclitaxel) was safer and more effective than a bare-metal stent; and that the administration of the anticoagulant medication bivalirudin enhanced safety and efficacy compared to the use of heparin + GPIIb/IIIa inhibitors.

25 Sep 2009

Everolimus-eluting stent efficient in treating native coronary artery lesions

Late-breaking data from SPIRIT IV, a large-scale multi-center study of nearly 4,000 patients in the U.S., shows that an everolimus-eluting stent demonstrated enhanced safety and efficacy in the treatment of de novo native coronary artery lesions when compared to a paclitaxel-eluting stent, and showed that "low late loss" may be achieved with drug-eluting stents without sacrificing safety.

24 Sep 2009

Clinical trial comparing Boston Scientific's coronary stent systems

Boston Scientific Corporation today welcomed one-year data from the SPIRIT IV clinical trial comparing the XIENCE V((R)) (PROMUS((R))) Everolimus-Eluting Coronary Stent System to the TAXUS((R)) Express2(TM) Paclitaxel-Eluting Coronary Stent System. The results support the benefits of paclitaxel-eluting stents in diabetic patients. The trial enrolled 3,690 patients, including 1,140 diabetics, the largest diabetic subset ever studied in a drug-eluting stent clinical trial.

24 Sep 2009

SPIRIT IV trial data demonstrates superior efficacy of XIENCE V stent system

Late-breaking data from the SPIRIT IV trial demonstrated that Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System achieved superiority in the key safety and efficacy measures of target lesion failure (TLF) and target lesion revascularization (TLR) compared to the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System (TAXUS) at one year.

24 Sep 2009

Three-year clinical results of Medtronic's Resolute Zotarolimus-Eluting Coronary Stent released

New clinical data released today at a major meeting of interventional cardiologists show strong and sustained efficacy and safety of the Resolute® Zotarolimus-Eluting Coronary Stent from Medtronic, Inc. (NYSE: MDT) in long-term patient follow-up.

22 Sep 2009

New sirolimus-eluting stent shows greater neointimal suppression than PES

A new type of sirolimus-eluting stent (SES) successfully showed significantly greater neointimal suppression than the paclitaxel-eluting stent (PES) with greater vessel wall integrity surrounding the stent, confirming the finding of superiority of the SES over the PES stent for the trial's primary endpoint of in-stent late loss.

22 Sep 2009

FDA approves Cordis Corporation's 2.25 mm CYPHER Stent

Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for a new, smaller version of the CYPHER® Sirolimus-eluting Coronary Stent, the world’s most studied drug-eluting stent that has been used to treat nearly 4 million people worldwide. The new 2.25 mm CYPHER® Stent is indicated for treatment of coronary blockages in small vessels, an often difficult-to-treat situation.

22 Sep 2009

Cook Medical launches the CE Marked Zilver PTX Drug-Eluting Peripheral Stent for treating PAD

In a breakthrough development that could dramatically reduce the number of leg amputations and painful bypass graft surgeries performed annually on European patients, a first-of-its kind drug-eluting stent for a widespread form of peripheral arterial disease (PAD) is now available to physicians throughout the European Union.

21 Sep 2009

Medtronic to showcase cardiovascular product portfolio at TCT 2009

Expecting new data on drug-eluting stents and transcatheter heart valves to feature prominently at Transcatheter Cardiovascular Therapeutics (TCT) 2009 next week in San Francisco, Medtronic, Inc. (NYSE: MDT), today announced plans to showcase its innovative cardiovascular product portfolio, technology pipeline and clinical research at the world’s premier annual meeting for interventional cardiologists.

19 Sep 2009

Patient enrollment for PLATINUM workhorse trial completed by Boston Scientific

Boston Scientific Corporation (NYSE: BSX) today announced the completion of patient enrollment in the workhorse portion of its PLATINUM clinical program. PLATINUM is a global, randomized, pivotal controlled trial designed to support U.S. Food and Drug Administration (FDA) and Japanese Ministry of Health, Labor and Welfare (MHLW) approval of the platinum chromium PROMUS((R)) Element(TM) Everolimus-Eluting Coronary Stent System.

19 Sep 2009

Chinese SFDA approves Abbott's XIENCE V drug eluting stent for treating coronary artery disease

Abbott (NYSE: ABT) announced today that the Chinese State Food and Drug Administration (SFDA) has approved its XIENCE V(R) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease (CAD) - the leading cause of death in China. XIENCE V is the only drug eluting stent to have demonstrated superiority over the TAXUS(R) Paclitaxel-Eluting Coronary Stent System (TAXUS) in the primary endpoints of two randomized, pivotal (phase III) clinical trials.

14 Sep 2009

Cordis enrolls first patient in the CYPRESS clinical study

Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today that the first patient has been enrolled in the CYPRESS study, which will assess clinical outcomes in a broad range of patients with coronary artery disease who take dual anti-platelet therapy after receiving a CYPHER Sirolimus-eluting Coronary Stent. The procedure was performed by Patrick Flaherty, D.O., Arkansas Heart Hospital in Little Rock, AK.

31 Aug 2009

Abbott introduces XIENCE PRIME Everolimus Eluting Coronary Stent System for global market

Abbott (NYSE: ABT) today announced at the European Society of Cardiology Congress the widespread availability of its next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.

31 Aug 2009

Medtronic's Q1 financial results announced

Medtronic, Inc. (NYSE:MDT) today announced financial results for its first quarter of fiscal year 2010, which ended July 31, 2009.

25 Aug 2009

Diabetes with coronary disease: A moving target amid evolving therapies

In an editorial in the current issue of the New England Journal of Medicine (NEJM), William E. Boden, M.D., professor of medicine and preventive medicine at the University at Buffalo, recommends that the results of the BARI-2D Trial published in that edition must be interpreted with "considerable caution."

8 Jun 2009

Boston Scientific launches 3rd generation platinum chromium drug-eluting stent

Boston Scientific Corporation today announced the launch of the Platinum chromium Taxus Element Paclitaxel-Eluting Coronary Stent System in select markets worldwide. The Taxus Element Stent features a new Platinum chromium alloy engineered specifically for coronary stent applications and represents the Company's third-generation drug-eluting stent (DES) technology.

19 May 2009

Anti-clotting action of clopidogrel (Plavix) reduced by common heartburn drugs

The anti-clotting action of the medication clopidogrel (Plavix) can be compromised by common drugs for the treatment of heartburn and ulcers resulting in a roughly 50% increase in the combined risk of hospitalization for heart attack, stroke and other serious cardiovascular illnesses, according to a new study presented today at the Society for Cardiovascular Angiography and Interventions (SCAI) 32nd Annual Scientific Sessions.

6 May 2009